MedTrace Logo

Muscle Parameters and Pathological Response in Breast Cancer Patients

NCT06151379 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2023-11-30

No results posted yet for this study

Summary

The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Conditions

  • Neoadjuvant Chemotherapy

Interventions

OTHER

Neoadjuvant therapy

To measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.

Sponsors & Collaborators

  • Acıbadem Atunizade Hospital

    lead OTHER

Principal Investigators

  • Aysun Isiklar, M.D. · Acıbadem Atunizade Hospital

Eligibility

Min Age
29 Years
Max Age
72 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2023-09-30
Completion
2023-10-20

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151379 on ClinicalTrials.gov